Metabolomic Biomarkers for Prognosis in Non-Muscle Invasive Bladder Cancer: A Comprehensive Systematic Review and Meta-Analysis
- 9 February 2024
- journal article
- research article
- Published by Springer Nature in Indian Journal of Clinical Biochemistry
- Vol. 40 (2) , 176-190
Abstract
The prognostic biomarkers, or metabolites, have gained relevance due to their significance in predicting clinical and therapeutic outcomes and guiding informed therapy options. This systematic review and meta-analysis aimed to evaluate the prognostic significance of metabolites in non-muscle-invasive bladder cancer (NMIBC) through an array of literature. The PubMed, Web of Science, Embase, and Cochrane Library databases were comprehensively searched for eligible studies published between January 2010 and August 2022, using related keywords and MeSH terms. Two reviewers performed the extraction process, and a third reviewer settled possible controversies. The New Castle Ottawa scale (NOS) was used to determine the quality of selected studies. Pooled hazard ratios (H.R.s) with 95% confidence intervals (C.I.s) were calculated to establish the relationship of metabolites with NMIBC outcomes (recurrence-free survival (RFS), progression-free survival (PFS), and overall survival (O.S.) to establish their prognostic roles. A total of 15 studies, with a sample size of 5491, were included and analyzed in this study. Various metabolites were found to be correlated with the outcomes of the study: PFS (pooled HR, 4.48; 95% CI, 1.70–11.80, p = 0.002), RFS (pooled HR, 2.85; 95% CI, 1.91–4.26; p = 0.00001), and OS (HR, 1.78; 95% CI, 1.07–2.98; p = 0.03). Pretreatment metabolites or markers in NMIBC patients had a relationship with recurrence prediction and disease outcomes in bladder cancer. Therefore, metabolites may equally serve as a critical, independent prognostic predictor for NMIBC patients. This could be considered in most related clinical decisions in bladder cancer.Keywords
Funding Information
- Indian Council of Medical Research (3/1/2(1)/URO/2022-NCD-II)
- University Grants Commission - South Eastern Regional Office (792/CSIRUGC NET DEC.2017)
This publication has 53 references indexed in Scilit:
- Prognostic Factors Including Ki-67 and p53 in Bacillus Calmette-Guérin-Treated Non-Muscle-Invasive Bladder Cancer: A Prospective StudyUrologia Internationalis, 2013
- PFKFB4 as a prognostic marker in non-muscle-invasive bladder cancerUrologic Oncology: Seminars and Original Investigations, 2012
- Expression profile of E-cadherin and N-cadherin in non-muscle-invasive bladder cancer as a novel predictor of intravesical recurrence following transurethral resectionUrologic Oncology: Seminars and Original Investigations, 2012
- Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancerBiomarkers, 2012
- HMOX1 is an Important Prognostic Indicator of Nonmuscle Invasive Bladder Cancer Recurrence and ProgressionJournal of Urology, 2011
- P16 reactivation induces anoikis and exhibits antitumour potency by downregulating Akt/survivin signalling in hepatocellular carcinoma cellsGut, 2010
- Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analysesEuropean Journal of Epidemiology, 2010
- Retinoblastoma protein expression predicts response to bacillus Calmette-Guérin immunotherapy in patients with T1G3 bladder cancerUrologic Oncology: Seminars and Original Investigations, 2010
- Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladderJournal of Clinical Pathology, 2006
- Pretreatment p53 Nuclear Overexpression as a Prognostic Marker in Superficial Bladder Cancer Treated with Bacillus Calmette–Guérin (BCG)European Urology, 2004